Press Releases Oncopeptides AB

Equities

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
2.685 ^SEK	+5.50%		+5.92%	-64.95%

Jul. 02	An undisclosed buyer acquired an 9.166336% stake in Oncopeptides AB (OM:ONCO) from Industrifonden for SEK 22.4 million.	CI
Jun. 27	Oncopeptides AB Selects First Candidate Drug from Its Spike Platform	CI

Number of shares and votes in Oncopeptides	Jul. 01	AQ
Number of shares and votes in Oncopeptides	Jun. 28	AQ
Oncopeptides selects first candidate drug from its SPiKE platform	Jun. 27	AQ
Bulletin from the Annual General Meeting in Oncopeptides AB (publ)	Jun. 03	AQ
Bulletin from the Annual General Meeting in Oncopeptides AB (publ)	May. 31	AQ
Number of shares and votes in Oncopeptides	May. 31	AQ
Oncopeptides : Kvartalsrapport Q1 2024 Transcript/td>	May. 30	PU
Oncopeptides : Interim Report Q1 2024 Transcript/td>	May. 30	PU
Oncopeptides : Interim Report Q1 2024 Presentation	May. 30	PU
Oncopeptides : Kvartalsrapport Q1 2024 Presentation	May. 30	PU
Oncopeptides issues warrants to fulfil its obligations under loan agreement with EIB	May. 30	AQ
Oncopeptides publishes Q1 report 2024	May. 30	AQ
Oncopeptides AB - First patients in Spain to be treated with Pepaxti	May. 28	AQ
First patients in Spain to be treated with Pepaxti	May. 27	AQ
Invitation to presentation of the Q1 report 2024	May. 21	AQ
Oncopeptides presents new data highlighting treatment benefits of Pepaxti in high-risk multiple myeloma patients at the COMy Congress	May. 16	AQ
Oncopeptides publishes final outcome in the fully guaranteed rights issue	May. 06	AQ
Annual General Meeting in Oncopeptides AB (publ)	Apr. 29	AQ
Oncopeptides publishes the 2023 Annual Report	Apr. 22	AQ
Oncopeptides publishes prospectus relating to the rights issue	Apr. 17	AQ

No results for this search